To study the tumor cell-intrinsic differences in response to commonly used therapies between dMMR and pMMR CRC, we generated a PDO cohort of six dMMR and six pMMR CRC-derived PDOs with annotated primary tumor location (sidedness) and BRAF- and KRAS-mutational status (Table 1). This evidence concerns the gene KRAS and neoplasm.